In a bid to bolster its immunology portfolio, Lilly has entered into an agreement to acquire Morphic in a deal worth up to US$3.2 B. Through this deal, Lilly will gain access to Morphic's primary candidate, MORF-057, which is currently being evaluated in two Phase II trials for ulcerative colitis and one Phase II study for Crohn's disease. This deal has the potential to significantly accelerate Lilly’s pipeline portfolio in inflammatory bowel disease (IBD) after the big pharma recently acquired DICE Therapeutics and its IBD treatment for a deal value of US$2.4 B.